Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Eur J Pharmacol

Retrieve available abstracts of 68 articles:
HTML format

Single Articles

    April 2021
  1. SILVA EAP, Carvalho JS, Dos Santos DM, Oliveira AMS, et al
    Cardiovascular effects of farnesol and its beta-cyclodextrin complex in normotensive and hypertensive rats.
    Eur J Pharmacol. 2021 Apr 2:174060. doi: 10.1016/j.ejphar.2021.174060.
    PubMed     Abstract available

    March 2021
  2. SHI Y, Jiang R, Qin X, Gao A, et al
    Up-regulation of nPKC contributes to proliferation of mice pulmonary artery smooth muscle cells in hypoxia-induced pulmonary hypertension.
    Eur J Pharmacol. 2021 Mar 18:174046. doi: 10.1016/j.ejphar.2021.174046.
    PubMed     Abstract available

    February 2021
  3. JASINSKA-STROSCHEIN M, Orszulak-Michalak D
    Reporting experimental studies on animals - The problems with translating of outcomes to clinical benefits. Methodological and statistical considerations: The example of pulmonary hypertension.
    Eur J Pharmacol. 2021;897:173952.
    PubMed     Abstract available

  4. GONZAGA-COSTA K, Vasconcelos-Silva AA, Rodrigues-Silva MJ, Rebouca CDSM, et al
    Soluble guanylate cyclase stimulator, trans-4-methoxy-beta-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
    Eur J Pharmacol. 2021;897:173948.
    PubMed     Abstract available

    November 2020
  5. LIU T, Hong L, Yang Y, Qiao X, et al
    Metformin reduces proteinuria in spontaneously hypertensive rats by activating the HIF-2alpha-VEGF-A pathway.
    Eur J Pharmacol. 2020 Nov 18:173731. doi: 10.1016/j.ejphar.2020.173731.
    PubMed     Abstract available

  6. ZIMMER A, Teixeira RB, Constantin RL, Campos-Carraro C, et al
    The progression of pulmonary arterial hypertension induced by monocrotaline is characterized by lung nitrosative and oxidative stress, and impaired pulmonary artery reactivity.
    Eur J Pharmacol. 2020 Nov 5:173699. doi: 10.1016/j.ejphar.2020.173699.
    PubMed     Abstract available

  7. ESCUDERO DS, Brea MS, Caldiz CI, Amarillo ME, et al
    PDE5 inhibition improves cardiac morphology and function in SHR by reducing NHE1 activity: Repurposing sildenafil for the treatment of hypertensive cardiac hypertrophy.
    Eur J Pharmacol. 2020 Nov 2:173724. doi: 10.1016/j.ejphar.2020.173724.
    PubMed     Abstract available

    October 2020
  8. MULVANEY EP, Reid HM, Bialesova L, Mendes-Ferreira P, et al
    Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension.
    Eur J Pharmacol. 2020 Oct 26:173658. doi: 10.1016/j.ejphar.2020.173658.
    PubMed     Abstract available

    September 2020
  9. GUIL MJ, Soria C, Seijas M, Bianciotti LG, et al
    Central endothelin ETB receptor activation reduces blood pressure and catecholaminergic activity in the olfactory bulb of deoxycorticosterone acetate-salt hypertensive rats.
    Eur J Pharmacol. 2020 Sep 4:173543. doi: 10.1016/j.ejphar.2020.173543.
    PubMed     Abstract available

    August 2020
  10. CHEN Y, Yuan T, Chen D, Liu S, et al
    Systematic analysis of molecular mechanism of resveratrol for treating pulmonary hypertension based on network pharmacology technology.
    Eur J Pharmacol. 2020 Aug 13:173466. doi: 10.1016/j.ejphar.2020.173466.
    PubMed     Abstract available

  11. FONSECA DA SILVA RCMVA, Boeing T, Bolda Mariano LN, Somensi LB, et al
    The pathophysiology of acute gastric ulcer development in normotensive and hypertensive rats: A comparative study.
    Eur J Pharmacol. 2020 Aug 12:173469. doi: 10.1016/j.ejphar.2020.173469.
    PubMed     Abstract available

  12. BRAGA CL, Felix NS, Teixeira DE, Vieira JB, et al
    Niclosamide attenuates lung vascular remodeling in experimental pulmonary arterial hypertension.
    Eur J Pharmacol. 2020 Aug 11:173438. doi: 10.1016/j.ejphar.2020.173438.
    PubMed     Abstract available

  13. HEGAZY M, El-Shafey M, Abulsoud AI, Elsadek BEM, et al
    Pioglitazone ameliorates high fat diet-induced hypertension and induces catechol o-methyl transferase expression in rats.
    Eur J Pharmacol. 2020 Aug 1:173383. doi: 10.1016/j.ejphar.2020.173383.
    PubMed     Abstract available

    June 2020
  14. RODRIGUEZ JE, Ruiz-Hernandez A, Hernandez-DiazCouder A, Huang F, et al
    Chronic diabetes and hypertension impair the in vivo functional response to phenylephrine independent of alpha1-adrenoceptor expression.
    Eur J Pharmacol. 2020;883:173283.
    PubMed     Abstract available

  15. SHIMIZU S, Nagao Y, Kataoka T, Kamada S, et al
    Protective effects of tadalafil on prostatic hyperplasia in spontaneously hypertensive rats.
    Eur J Pharmacol. 2020 Jun 27:173313. doi: 10.1016/j.ejphar.2020.173313.
    PubMed     Abstract available

  16. DJOKIC V, Jankovic S, Labudovic-Borovic M, Rakocevic J, et al
    Pregnancy-induced hypertension decreases Kv1.3 potassium channel expression and function in human umbilical vein smooth muscle.
    Eur J Pharmacol. 2020 Jun 17:173281. doi: 10.1016/j.ejphar.2020.173281.
    PubMed     Abstract available

  17. AZHAR AS, Zaher ZF, Ashour OM, Abdel-Naim AB, et al
    2-Methoxyestradiol ameliorates metabolic syndrome-induced hypertension and catechol-O-methyltransferase inhibited expression and activity in rats.
    Eur J Pharmacol. 2020 Jun 13:173278. doi: 10.1016/j.ejphar.2020.173278.
    PubMed     Abstract available

  18. LIU Y, Shen W, Chen Q, Cao Q, et al
    Inhibition of RAGE by FPS-ZM1 alleviates renal injury in spontaneously hypertensive rats.
    Eur J Pharmacol. 2020 Jun 2:173228. doi: 10.1016/j.ejphar.2020.173228.
    PubMed     Abstract available

    May 2020
  19. OYAGBEMI AA, Omobowaleb TO, Adejumobi OA, Owolabi AM, et al
    Antihypertensive power of Naringenin is mediated via attenuation of mineralocorticoid receptor (MCR)/ angiotensin converting enzyme (ACE)/ kidney injury molecule (Kim-1) signaling pathway.
    Eur J Pharmacol. 2020 May 15:173142. doi: 10.1016/j.ejphar.2020.173142.
    PubMed     Abstract available

    November 2019
  20. ABOUELKHEIR M, El-Metwally TH
    Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme.
    Eur J Pharmacol. 2019;862:172638.
    PubMed     Abstract available

  21. NOVELLI D, Fumagalli F, Staszewsky L, Ristagno G, et al
    Monocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor.
    Eur J Pharmacol. 2019 Nov 4:172777. doi: 10.1016/j.ejphar.2019.172777.
    PubMed     Abstract available

    October 2019
  22. ZHU C, Tian L, Yang H, Chen P, et al
    Mitochondrial outer membrane voltage-dependent anion channel is involved in renal dysfunction in a spontaneously hypertensive rat carrying transfer RNA mutations.
    Eur J Pharmacol. 2019 Oct 13:172622. doi: 10.1016/j.ejphar.2019.172622.
    PubMed     Abstract available

    September 2019
  23. LIU H, Ge XY, Huang N, Liu T, et al
    Up-regulation of cullin7 promotes proliferation and migration of pulmonary artery smooth muscle cells in hypoxia-induced pulmonary hypertension.
    Eur J Pharmacol. 2019 Sep 26:172698. doi: 10.1016/j.ejphar.2019.172698.
    PubMed     Abstract available

  24. LIU T, Zou XZ, Huang N, Ge XY, et al
    Down-regulation of miR-204 attenuates endothelial-mesenchymal transition by enhancing autophagy in hypoxia-induced pulmonary hypertension.
    Eur J Pharmacol. 2019 Sep 19:172673. doi: 10.1016/j.ejphar.2019.172673.
    PubMed     Abstract available

  25. ZHANG X, Mao A, Xiao W, Zhang P, et al
    Morin induces endothelium-dependent relaxation by activating TRPV4 channels in rat mesenteric arteries.
    Eur J Pharmacol. 2019;859:172561.
    PubMed     Abstract available

    June 2019
  26. SINGH A, Kumar BS, Iqbal H, Alam S, et al
    Antihypertensive activity of diethyl-4,4'-dihydroxy-8,3'-neolign-7,7'-dien-9,9'-dionate: A continuation study in L-NAME treated wistar rats.
    Eur J Pharmacol. 2019;858:172482.
    PubMed     Abstract available

  27. WANG EL, Jia MM, Luo FM, Li T, et al
    Coordination between NADPH oxidase and vascular peroxidase 1 promotes dysfunctions of endothelial progenitor cells in hypoxia-induced pulmonary hypertensive rats.
    Eur J Pharmacol. 2019 Jun 16:172459. doi: 10.1016/j.ejphar.2019.172459.
    PubMed     Abstract available

    May 2019
  28. XING XQ, Li B, Xu SL, Zhang CF, et al
    5-Aza-2'-deoxycytidine, a DNA methylation inhibitor, attenuates hypoxic pulmonary hypertension via demethylation of the PTEN promoter.
    Eur J Pharmacol. 2019 May 11. pii: S0014-2999(19)30325.
    PubMed     Abstract available

  29. ZHOU Y, Liu X, Zhang X, Wen J, et al
    Decreased vasodilatory effect of Tanshinone A Sodium Sulfonate on mesenteric artery in hypertension.
    Eur J Pharmacol. 2019;854:365-371.
    PubMed     Abstract available

    April 2019
  30. MAZUR I, Belenichev I, Kucherenko L, Bukhtiyarova N, et al
    Antihypertensive and cardioprotective effects of new compound 1-(beta-phenylethyl)-4-amino-1,2,4-triazolium bromide (Hypertril).
    Eur J Pharmacol. 2019 Apr 9. pii: S0014-2999(19)30241.
    PubMed     Abstract available

    February 2019
  31. SEN Z, Weida W, Li Y, Zhaojun L, et al
    Nicousamide attenuates renal dysfunction and glomerular injury in remnant kidneys by inhibiting TGF-beta1 internalisation and renin activity.
    Eur J Pharmacol. 2019;845:74-84.
    PubMed     Abstract available

  32. CANTONI S, Cavalli S, Pastore F, Accetta A, et al
    Pharmacological characterization of a highly selective Rho-kinase (ROCK) inhibitor and its therapeutic effects in experimental pulmonary hypertension.
    Eur J Pharmacol. 2019 Feb 9. pii: S0014-2999(19)30102.
    PubMed     Abstract available

  33. YU X, Zhao X, Zhang J, Li Y, et al
    Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension.
    Eur J Pharmacol. 2019 Feb 9. pii: S0014-2999(19)30095.
    PubMed     Abstract available

  34. KAMADA R, Yokoshiki H, Mitsuyama H, Watanabe M, et al
    Arrhythmogenic beta-adrenergic signaling in cardiac hypertrophy: The role of small-conductance calcium-activated potassium channels via activation of CaMKII.
    Eur J Pharmacol. 2019;844:110-117.
    PubMed     Abstract available

  35. MARCUS AJ, Iezhitsa I, Agarwal R, Vassiliev P, et al
    Intraocular pressure-lowering effects of imidazo[1,2-a]- and pyrimido[1,2-a]benzimidazole compounds in rats with dexamethasone-induced ocular hypertension.
    Eur J Pharmacol. 2019 Feb 1. pii: S0014-2999(19)30082.
    PubMed     Abstract available

    January 2019
  36. LI T, Luo XJ, Wang EL, Li NS, et al
    Magnesium lithospermate B prevents phenotypic transformation of pulmonary arteries in rats with hypoxic pulmonary hypertension through suppression of NADPH oxidase.
    Eur J Pharmacol. 2019 Jan 16. pii: S0014-2999(19)30028.
    PubMed     Abstract available

    November 2018
  37. DAI G, Li B, Xu Y, Zeng Z, et al
    Oxymatrine prevents the development of monocrotaline-induced pulmonary hypertension via regulation of the N(G), N(G)-dimethyl-L-arginine metabolism pathways in rats.
    Eur J Pharmacol. 2018 Nov 9. pii: S0014-2999(18)30656.
    PubMed     Abstract available

    October 2018
  38. HONG XY, Hong X, Gu WW, Lin J, et al
    Cardioprotection and improvement in endothelial-dependent vasodilation during late-phase of whole body hypoxic preconditioning in spontaneously hypertensive rats via VEGF and endothelin-1.
    Eur J Pharmacol. 2018;842:79-88.
    PubMed     Abstract available

  39. IGREJA B, Pires NM, Wright LC, Soares-da-Silva P, et al
    Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure.
    Eur J Pharmacol. 2018;842:125-132.
    PubMed     Abstract available

  40. YADAV VR, Teng B, Mustafa SJ
    Enhanced A1 adenosine receptor-induced vascular contractions in mesenteric artery and aorta of in L-NAME mouse model of hypertension.
    Eur J Pharmacol. 2018 Oct 19. pii: S0014-2999(18)30607.
    PubMed     Abstract available

  41. NASCIMENTO RA, Possomato-Vieira JS, Goncalves-Rizzi VH, Bonacio GF, et al
    Hypertension, augmented activity of matrix metalloproteinases-2 and -9 and angiogenic imbalance in hypertensive pregnancy are attenuated by doxycycline.
    Eur J Pharmacol. 2018;840:60-69.
    PubMed     Abstract available

  42. SU J, Huang M
    Etidronate protects chronic ocular hypertension induced retinal oxidative stress and promotes retinal ganglion cells growth through IGF-1 signaling pathway.
    Eur J Pharmacol. 2018 Oct 13. pii: S0014-2999(18)30577.
    PubMed     Abstract available

    July 2018
  43. MORRIS R, Spencer SK, Barnes A, Bowles T, et al
    Attenuation of oxidative stress and hypertension in an animal model of HELLP syndrome.
    Eur J Pharmacol. 2018 Jul 13. pii: S0014-2999(18)30380.
    PubMed     Abstract available

  44. TAHARA A, Takasu T
    Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
    Eur J Pharmacol. 2018;830:68-75.
    PubMed     Abstract available

  45. CARVALHO DS, de Almeida AA, Borges AF, Vannucci Campos D, et al
    Treatments for diabetes mellitus type II: New perspectives regarding the possible role of calcium and cAMP interaction.
    Eur J Pharmacol. 2018;830:9-16.
    PubMed     Abstract available

    June 2018
  46. ZHANG C, Booz GW, Yu Q, He X, et al
    Conflicting roles of 20-HETE in hypertension and renal end organ damage.
    Eur J Pharmacol. 2018 Jun 7. pii: S0014-2999(18)30342.
    PubMed     Abstract available

    May 2018
  47. ZHOU Y, Tian X, Wang X, Wang Y, et al
    Quaternary ammonium salt of U50,488H elicits protective effects against hypoxic pulmonary hypertension.
    Eur J Pharmacol. 2018 May 18. pii: S0014-2999(18)30288.
    PubMed     Abstract available

    April 2018
  48. LAN TH, Chen XL, Wu YS, Qiu HL, et al
    3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.
    Eur J Pharmacol. 2018 Apr 14. pii: S0014-2999(18)30222.
    PubMed     Abstract available

    February 2018
  49. BHAT L, Hawkinson J, Cantillon M, Reddy DG, et al
    Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
    Eur J Pharmacol. 2018 Feb 14. pii: S0014-2999(18)30096.
    PubMed     Abstract available

    January 2018
  50. GONCALVES-RIZZI VH, Possomato-Vieira JS, Nascimento RA, Caldeira-Dias M, et al
    Maternal hypertension and feto-placental growth restriction is reversed by sildenafil: Evidence of independent effects of circulating nitric oxide levels.
    Eur J Pharmacol. 2018 Jan 17. pii: S0014-2999(18)30017.
    PubMed     Abstract available

  51. MARTINS-OLIVEIRA A, Guimaraes DA, Ceron CS, Rizzi E, et al
    Direct renin inhibition is not enough to prevent reactive oxygen species generation and vascular dysfunction in renovascular hypertension.
    Eur J Pharmacol. 2018;821:97-104.
    PubMed     Abstract available

  52. BELADIYA JV, Chaudagar KK, Mehta AA
    A protective role of Galphaq-RGS2 loop activator on streptozotocin induced diabetic complications in rats: An independent on elevated serum glucose level modulation.
    Eur J Pharmacol. 2018;818:141-147.
    PubMed     Abstract available

    December 2017
  53. ZHANG N, Dong M, Luo Y, Zhao F, et al
    Danshensu prevents hypoxic pulmonary hypertension in rats by inhibiting the proliferation of pulmonary artery smooth muscle cells via TGF-beta-smad3-associated pathway.
    Eur J Pharmacol. 2017 Dec 5. pii: S0014-2999(17)30794.
    PubMed     Abstract available

  54. LEBLANC C, Tabrizchi R
    Role of beta2- and beta3-adrenoceptors in arterial stiffness in a state of hypertension.
    Eur J Pharmacol. 2017 Dec 2. pii: S0014-2999(17)30783.
    PubMed     Abstract available

    November 2017
  55. WU Y, Qian Z, Fu S, Yue Y, et al
    IcarisideII improves left ventricular remodeling in spontaneously hypertensive rats by inhibiting the ASK1-JNK/p38 signaling pathway.
    Eur J Pharmacol. 2017 Nov 21. pii: S0014-2999(17)30768.
    PubMed     Abstract available

    October 2017
  56. ZHANG W, Zhu T, Wu W, Ge X, et al
    LOX-1 mediated phenotypic switching of pulmonary arterial smooth muscle cells contributes to hypoxic pulmonary hypertension.
    Eur J Pharmacol. 2017;818:84-95.
    PubMed     Abstract available

    September 2017
  57. SUN P, Sun H, Zhang W, Du Z, et al
    Antagonist of thromboxane A2 receptor by SQ29548 lowers DOCA-induced hypertension in diabetic rats.
    Eur J Pharmacol. 2017 Sep 20. pii: S0014-2999(17)30614.
    PubMed     Abstract available

    August 2017
  58. SILVA BR, Pernomian L, De Paula TD, Grando MD, et al
    Endothelial nitric oxide synthase and cyclooxygenase are activated by hydrogen peroxide in renal hypertensive rat aorta.
    Eur J Pharmacol. 2017 Aug 2. pii: S0014-2999(17)30503.
    PubMed     Abstract available

    July 2017
  59. SINGH A, Kumar BS, Alam S, Iqbal H, et al
    Corrigendum to "Diethyl-4,4'-dihydroxy-8,3'-neolign-7,7'-dien-9,9'-dionate exhibits antihypertensive activity in rats through increase in intracellular cGMP level and blockade of calcium channels" [Eur. J. Pharmacol. 799 (2017) 84-93].
    Eur J Pharmacol. 2017;806:111.

  60. JIANG D, Kawagoe Y, Kuwasako K, Kitamura K, et al
    Inhibitory effects of losartan and azelnidipine on augmentation of blood pressure variability induced by angiotensin II in rats.
    Eur J Pharmacol. 2017;806:91-95.
    PubMed     Abstract available

    June 2017
  61. YAMAMURA A, Fujitomi E, Ohara N, Tsukamoto K, et al
    Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro.
    Eur J Pharmacol. 2017 Jun 8. pii: S0014-2999(17)30400.
    PubMed     Abstract available

    May 2017
  62. BHAT L, Hawkinson J, Cantillon M, Reddy DG, et al
    RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Eur J Pharmacol. 2017 May 31. pii: S0014-2999(17)30380.
    PubMed     Abstract available

  63. BHAT L, Hawkinson J, Cantillon M, Reddy DG, et al
    RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats.
    Eur J Pharmacol. 2017 May 30. pii: S0014-2999(17)30381.
    PubMed     Abstract available

  64. SAVIGNANO FA, Crajoinas RO, Pacheco BPM, Campos LCG, et al
    Attenuated diuresis and natriuresis in response to glucagon-like peptide-1 in hypertensive rats are associated with lower expression of the glucagon-like peptide-1 receptor in the renal vasculature.
    Eur J Pharmacol. 2017 May 30. pii: S0014-2999(17)30386.
    PubMed     Abstract available

    March 2017
  65. BOMFIM GH, Mendez-Lopez I, Fernandez-Morales JC, Padin JF, et al
    Electrophysiological properties and augmented catecholamine release from chromaffin cells of WKY and SHR rats contributing to the hypertension development elicited by chronic EtOH consumption.
    Eur J Pharmacol. 2017 Mar 16. pii: S0014-2999(17)30179.
    PubMed     Abstract available

    February 2017
  66. YOON JJ, Lee YJ, Han BH, Choi ES, et al
    Protective effect of betulinic acid on early atherosclerosis in diabetic apolipoprotein-E gene knockout mice.
    Eur J Pharmacol. 2017;796:224-232.
    PubMed     Abstract available

    January 2017
  67. AL SULEIMANI YM, Al Mahruqi AS
    The endogenous lipid N-arachidonoyl glycine is hypotensive and nitric oxide-cGMP-dependent vasorelaxant.
    Eur J Pharmacol. 2017;794:209-215.
    PubMed     Abstract available

    December 2016
  68. MOSTAFA DK, Nasra RA, Zahran N, Ghoneim MT, et al
    Pleiotropic protective effects of Vitamin D against high fat diet-induced metabolic syndrome in rats: One for all.
    Eur J Pharmacol. 2016;792:38-47.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.